Matt McNally
Throughout his career, Matt McNally has guided brands to maximize their impact through periods of rapidly changing audience behavior. He has successfully helped clients shift their approach to media from simply a planning and buying space to a strategic function that leverages new methods of communication and technology. Now as Chief Executive Officer of Outcome Health, he s doing the same thing for the point of care channel. He has been honored repeatedly as one of the most influential people in the life sciences industry, and, in 2019, was named to the “Health Influencer 50” by PR Week and MM&M.
Report: Giants sign ex-A s starter Scott Kazmir to minor-league deal lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Vivor CEO highlights patient financial assistance platform for hospitals and health systems
Vivor CEO and Co-founder Ian Manners talks about the origins of the financial assistance startup and their mission to eliminate out-of-pocket costs as a barrier to care.
Shares1
Vivor CEO and co-founder Ian Manners talks about the origins of the financial assistance startup and their mission to eliminate out-of-pocket costs as a barrier to care.
Why did you start this company?
In my previous career as a management consultant, I worked with a lot of pharma companies that were trying to figure out all the reasons why patients might not be able to start or continue treatment for life-threatening conditions like cancer. Of course, most of these reasons were clinical ones serious side effects, for example but I was really surprised how often the non-clinical concerns like out-of-pocket cost were causing patients to skip or delay care.
MedCity News
Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver
Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.
Shares0
The next hurdles for gene-editing medicines are therapies that do their work inside the patient. But so far, biotechs have had a hard time developing such in vivo therapies that target anything other than the liver. Beam Therapeutics has acquired a startup whose technology could deliver the biotech’s genetic medicines to more tissues in the body, broadening the potential to address more diseases.